Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Amortization of Deferred Charges: 2019-2021

Historic Amortization of Deferred Charges for UroGen Pharma (URGN) over the last 2 years, with Jun 2021 value amounting to $232,000.

  • UroGen Pharma's Amortization of Deferred Charges fell 38.79% to $232,000 in Q2 2021 from the same period last year, while for Jun 2021 it was $1.3 million, marking a year-over-year increase of 4.19%. This contributed to the annual value of $1.6 million for FY2020, which is 58.37% up from last year.
  • UroGen Pharma's Amortization of Deferred Charges amounted to $232,000 in Q2 2021, which was down 2.11% from $237,000 recorded in Q1 2021.
  • In the past 5 years, UroGen Pharma's Amortization of Deferred Charges registered a high of $494,000 during Q4 2020, and its lowest value of $232,000 during Q2 2021.
  • In the last 3 years, UroGen Pharma's Amortization of Deferred Charges had a median value of $269,000 in 2019 and averaged $312,500.
  • In the last 5 years, UroGen Pharma's Amortization of Deferred Charges skyrocketed by 69.18% in 2020 and then tumbled by 38.79% in 2021.
  • Over the past 3 years, UroGen Pharma's Amortization of Deferred Charges (Quarterly) stood at $292,000 in 2019, then surged by 69.18% to $494,000 in 2020, then crashed by 38.79% to $232,000 in 2021.
  • Its Amortization of Deferred Charges was $232,000 in Q2 2021, compared to $237,000 in Q1 2021 and $494,000 in Q4 2020.